Epidermal growth factor family receptors and inhibitors: Radiation response modulators

Seminars in Radiation Oncology

Volumn 13, Issue 1, 2003, Pages 22-30

  Sartor, Carolyn I ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANERTINIB; CETUXIMAB; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; GEFITINIB; GSK 2016; TRASTUZUMAB; UNCLASSIFIED DRUG; ZD 1389;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER; CANCER RADIOTHERAPY; CARDIOTOXICITY; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DNA REPAIR; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG TOLERABILITY; HEAD AND NECK CANCER; HEART DISEASE; HUMAN; IONIZING RADIATION; MULTIMODALITY CANCER THERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION INJURY; RADIATION RESPONSE; RADIOSENSITIVITY; RADIOSENSITIZATION; RECEPTOR INTRINSIC ACTIVITY; REVIEW; SIGNAL TRANSDUCTION;

EID: 0037270588     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1053/srao.2003.50003     Document Type: Review

References (55)

1. Yarden Y: The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities. Eur J Cancer 4:S3-8, 2001 (suppl)
2. Baselga J: The EGFR as a target for anticancer therapy - Focus on cetuximab. Eur J Cancer 4:S16-22, 2001 (suppl)
3. Klapper LN, Waterman H, Sela M, et al: Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. Cancer Res 60:3384-3388, 2000
4. Ciardiello F, Tortora G: A novel approach in the treatment of cancer: Targeting the epidermal growth factor receptor. Clin Cancer Res 7:2958-2970, 2001
5. Barker FG 2nd, Simmons ML, Chang SM, et al: EGFR overexpression and radiation response in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 51:410-418, 2001
6. Gupta AK, McKenna WG, Weber CN, et al: Local recurrence in head and neck cancer: Relationship to radiation resistance and signal transduction. Clin Cancer Res 8:885-892, 2002
7. Sheridan MT, O'Dwyer T, Seymour CB, et al: Potential indicators of radiosensitivity in squamous cell carcinoma of the head and neck. Radiat Oncol Investig 5:180-186, 1997
8. FitzGerald TJ, Henault S, Sakakeeny M, et al: Expression of transfected recombinant oncogenes increases radiation resistance ofclonal hematopoietic and fibroblast cell lines selectively at clinical low dose rate. Radiat Res 122:44-52, 1990
9. Balaban N, Moni J, Shannon M, et al: The effect of ionizing radiation on signal transduction: Antibodies to EGF receptor sensitize A431 cells to radiation. Biochim Biophys Acta 1314:147-156, 1996
10. Wollman R, Yahalom J, Maxy R, et al: Effect of epidermal growth factor on the growth and radiation sensitivity of human breast cancer cells in vitro. Int J Radiat Oncol Biol Phys 30:91-98, 1994
11. Kwok TT, Sutherland RM: Differences in EGF related radiosensitisation of human squamous carcinoma cells with high and low numbers of EGF receptors. Br J Cancer 64:251-254, 1991
12. Bonner JA, Maihle NJ, Folven BR, et al: The interaction of epidermal growth factor and radiation in human head and neck squamous cell carcinoma cell lines with vastly different radiosensitivities. Int J Radiat Oncol Biol Phys 29:243-247, 1994
13. Schmidt-Ullrich RK, Mikkelsen RB, Dent P, et al: Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene 15:1191-1197, 1997
14. Todd DG, Mikkelsen RB, Rorrer WK, et al: Ionizing radiation stimulates existing signal transduction pathways involving the activation of epidermal growth factor receptor and ERBB-3, and changes of intracellular calcium in A431 human squamous carcinoma cells. J Recept Signal Transduct Res 19:885-908, 1999
15. Carter S, Auer KL, Reardon DB, et al: Inhibition of the mitogen activated protein (MAP) kinase cascade potentiates cell killing by low dose ionizing radiation in A431 human squamous carcinoma cells. Oncogene 16:2787-2796, 1998
16. Schmidt-Ullrich RK, Valerie KC, Chan W, et al: Altered expression of epidermal growth factor receptor and estrogen receptor in MCF-7 cells after single and repeated radiation exposures. Int J Radiat Oncol Biol Phys 29:813-819, 1994
17. Zhou H, Dy R, Sartor C: A New Series of Radioresistant Breast Cancer Cell Lines Demonstrate Frequent Alterations in EGFR Signaling. Gordon Research Conference, Ventura, CA, January 28-February 2, 2001
18. Haffty BG, Brown F, Carter D, et al: Evaluation of HER-2 neu oncoprotein expression as a prognostic indicator of local recurrence in conservatively treated breast cancer: A case-control study. Int J Radiat Oncol Biol Phys 35:751-757, 1996
19. Pirollo KF, Tong YA, Villegas Z, et al: Oncogene-transformed NIH 3T3 cells display radiation resistance levels indicative of a signal transduction pathway leading to the radiation-resistant phenotype. Radiat Res 135:234-243, 1993
20. Pietras RJ, Poen JC, Gallardo D, et al: Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res 59:1347-1355, 2001
21. Harari PM, Huang SM: Radiation response modification following molecular inhibition of epidermal growth factor receptor signaling. Semin Radiat Oncol 11:281-289, 2001
22. Harari PM, Huang SM: Head and neck cancer as a clinical model for molecular targeting of therapy: Combining EGFR blockade with radiation. Int J Radiat Oncol Biol Phys 49:427-433, 2001
23. Nasu S, Ang KK, Fan Z, et al: C225 antiepidermal growth factor receptor antibody enhances tumor radiocurability. Int J Radiat Oncol Biol Phys 51:474-477, 2001
24. Raben D, Buchsbaum D, Gillespie Y, et al: Treatment of human intracranial gliomas with chimeric monoclonal antibody against the epidermal growth factor receptor increases survival of nude mice when treated concurrently with irradiation. American Association for Cancer Research 90th Annual Meeting. Philadelphia, PA, Cancer Research, A1224, 1999
25. Helfrich B, Phistry M, Chan D, et al: ZD1839 (Iressa), a Selective EGFR-TKI, Enhances Radiation and Chemotherapy Cytotoxicity in EGFR Positive Human Non-Small Cell Lung Cancer Cells (NSCLC) in Vitro. Molecular Biology and New Treatment Strategies: Cancer Research in the 21st Century, Maui, HI, B10, 2001
26. Williams K, Telfer B, Stratford I, et al: Combination of ZD1839 (Iressa), and EGFR-TKI, and radiotherapy increases antitumor efficacy in a human colon cancer xenograft. American Association for Cancer Research 92nd Annual Meeting, New Orleans, LA, Cancer Research, A3480, 2001
27. She Y, Lee F, Haimovitz-Friedman A, et al: The selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) enhances radiation sensitivity of human tumor xenografts in nude mice. American Association for Cancer Research 93rd Annual Meeting, San Francisco, CA, Cancer Research, A3894, 2002
28. Stea B, Falsey R, Carey S, et al: Growth inhibition and radiosensitization of glioblastoma Multiforme by the tyrosine kinase inhibitor ZD1839 (Iressa). American Association for Cancer Research 93rd Annual Meeting, San Francisco, CA, Cancer Research, A3899, 2002
29. Anido J, Albanell J, Rojo F, et al: ZD1839 (Iressa), a specific epidermal growth factor receptor tyrosine kinase inhibitor, induces the formatin of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2 overexpressing breast cancer cells. American Association for Cancer Research 93rd Annual Meeting, San Francisco, CA, Cancer Research, A3881, 2002
30. Christensen JG, Schreck RE, Chan E, et al: High levels of HER-2 expression alter the ability of epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitors to inhibit EGFR phosphorylation in vivo. Clin Cancer Res 7:4230-4238, 2001
31. Rao GS, Murray S, Ethier SP: Radiosensitization of human breast cancer cells by a novel ErbB family receptor tyrosine kinase inhibitor. Int J Radiat Oncol Biol Phys 48:1519-1528, 2000
32. Rusnak DW, Affleck K, Cockerill SG, et al: The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. Cancer Res 61: 7196-7203, 2001
33. Contessa JN, Reardon DB, Todd D, et al: The inducible expression of dominant-negative epidermal growth factor receptor-CD533 results in radiosensitization of human mammary carcinoma cells. Clin Cancer Res 5:405-411, 1999
34. Lammering G, Hewit TH, Hawkins WT, et al: Epidermal growth factor receptor as a genetic therapy target for carcinoma cell radiosensitization. J Natl Cancer Inst 93: 921-929, 2001
35. O'Rourke DM, Kao GD, Singh N, et al: Conversion of a radioresistant phenotype to a more sensitive one by disabling erbB receptor signaling in human cancer cells. P Natl Acad Sci 95:10842-10847, 1998
36. Bonner J, Ezekiel M, Robert F, et al: Continued response following treatment with IMC-C225, and EGFr MoAb combined with RT in advanced head and neck malignancies. American Society of Clinical Oncology 36th Annual Meeting, New Orleans, LA: Journal of Clinical Oncology; 2000:5F.
37. Raben D, Helfrich BA, Chan D, et al: ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer. Semin Oncol 29:37-46, 2002
38. Seidman A, Hudis C, Pierri MK, et al: Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20:1215-1221, 2002
39. Early Breast Cancer Trialists' Collaborative Group: Favourable and unfavorable effects on long-term survival of radiotherapy for early breast cancer: An overview of the randomised trials. Lancet 355:1757-1770, 2000
40. Rohrbach S, Yan X, Weinberg EO, et al: Neuregulin in cardiac hypertrophy in rats with aortic stenosis. Differential expression of erbB2 and erbB4 receptors. Circulation 100:407-412, 1999
41. Davis RJ: Signal transduction by the JNK group of MAP kinases. Cell 103:239-252, 2000
42. Canman CE, Kastan MB: Signal transduction. Three paths to stress relief. Nature 384:213-214, 1996
43. Verheij M, Bose R, Lin XH, et al: Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis. Nature 380:75-79, 1996
44. Ruiter GA, Zerp SF, Bartelink H, et al: Alkyl-lysophospholipids activate the SAPK/JNK pathway and enhance radiation-induced apoptosis. Cancer Res 59:2457-2463, 1999
45. Reardon DB, Contessa JN, Mikkelsen RB, et al: Dominant negative EGFR-CD533 and inhibition of MAPK modify JNK1 activation and enhance radiation toxicity of human mammary carcinoma cells. Oncogene 18:4756-4766, 1999
46. Brognard J, Clark AS, Ni Y, et al: Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 61:3986-3997, 2001
47. Grana T, Rusyn E, Zhou H, et al: Ras mediates radioresistance through both PI3-K-dependent and Raf-dependent but MEK-independent signaling pathways. Cancer Res 62:4142-4150, 2002
48. Grana T, Zhou H, Sartor C, et al: Ras-mediated radiation resistance via autocrine pathways. Radiation Research Society 49th Annual Meeting, Reno, NV, P29-288, 2002
49. Baldwin AS: Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest 107:241-246, 2001
50. Pianetti S, Arsura M, Romieu-Mourez R, et al: Her-2/neu overexpression induces NF-kappaB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IkappaB-alpha that can be inhibited by the tumor suppressor PTEN. Oncogene 20:1287-1299, 2001
51. Zhou BP, Hu MC, Miller SA, et al: HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway. J Biol Chem 275:8027-8031, 2000
52. Huang SM, Bock JM, Harari PM: Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 59:1935-1940, 1999
53. Milas L, Mason K, Hunter N, et al: In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 6:701-708, 2000
54. Huang SM, Harari PM: Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: Inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 6:2166-2174, 2000
55. Ciardiello F, Caputo R, Bianco R, et al: Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 7:1459-1465, 2001